UniProtKB/Swiss-Prot P22681: Variant p.Lys287Arg

E3 ubiquitin-protein ligase CBL
Gene: CBL
Chromosomal location: 11q23.3
Variant information

Variant position:  287
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:  Unclassified
The variants are classified into three categories: Disease, Polymorphism and Unclassified.
  • Disease: Variants have been found in patients and disease-association is reported in literature. However, this classification is not a definitive assessment of variant pathogenicity.
  • Polymorphism: No disease-association has been reported.
  • Unclassified: Variants have been found in patients but disease-association remains unclear.

Residue change:  From Lysine (K) to Arginine (R) at position 287 (K287R, p.Lys287Arg).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:  Similar physico-chemical property. Both residues are large size and basic.
The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:  2
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description:  Found in patients with acute myeloid leukemia; unknown pathological significance.
Any additional useful information about the variant.



Sequence information

Variant position:  287
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:  906
The length of the canonical sequence.

Location on the sequence:   GYMAFLTYDEVKARLQKFIH  K PGSYIFRLSCTRLGQWAIGY
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Residue conservation: 
The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         GYMAFLTYDEVKARLQKFIHKPGSYIFRLSCTRLGQWAIGY

Mouse                         GYMAFLTYDEVKARLQKFIHKPGSYIFRLSCTRLGQWAIGY

Fission yeast                 G-------------------NPTRSVLQVHLAKLMKAKHAF

Sequence annotation in neighborhood:  
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.

TypePositionsDescription
Chain 1 – 906 E3 ubiquitin-protein ligase CBL
Domain 47 – 351 Cbl-PTB
Region 1 – 357 Sufficient for interaction with EPHB1
Region 249 – 351 SH2-like
Binding site 294 – 294 Phosphotyrosine
Mutagenesis 294 – 294 R -> K. Abolishes interaction with ZAP70.
Mutagenesis 306 – 306 G -> E. Abolishes interaction with ZAP70 and EPHB1, but does not affect interaction with SLA.


Literature citations

Novel oncogenic mutations of CBL in human acute myeloid leukemia that activate growth and survival pathways depend on increased metabolism.
Fernandes M.S.; Reddy M.M.; Croteau N.J.; Walz C.; Weisbach H.; Podar K.; Band H.; Carroll M.; Reiter A.; Larson R.A.; Salgia R.; Griffin J.D.; Sattler M.;
J. Biol. Chem. 285:32596-32605(2010)
Cited for: VARIANTS ARG-287; SER-LYS-365 INS; HIS-371 AND LEU-499; CHARACTERIZATION OF VARIANTS SER-LYS-365 INS AND HIS-371; PHOSPHORYLATION AT TYR-674; TYR-700 AND TYR-774;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.